Diagnosis and treatment of neurogenic heterotpic ossification: patent no. EP 23382063
Heterotopic Ossification (HO) is the presence of mature lamellar bone in extra-skeletal soft tissues. Currently there are no markers that allow an early diagnosis of this pathology to be established. Likewise, the current therapies used for its management have low-effective rates, some of them are highly aggressive and associated with side effects and complications. This patent focuses on the identification of new serum markers that make it possible to predict the development of OH, as well as on the search for new therapeutic tools that make it possible to reduce the levels of the identified biomarkers.
New treatment for abnormal bone growth: patent no. EP19382094
Heterotopic ossification consists in the abnormal growth of bone in soft tissues This condition that comes from genetic or acquired origin diminishes the quality of life of patients. There is currently no treatment to address the root of this disease or to prevent its recurrence after surgery. Our group has patented a therapy that modifies the balance between bone and fat, thus inhibiting bone growth and its associated complications.
New active ingredients to block innate immune responses mediated by TLR4, IL1R, COX1/2, and/or RBP4: patent no. EP 22 382 696
Innate immunity plays an essential role in the pathogenesis and progression of multiple rheumatic pathologies, but also of other diseases such as COVID19, sepsis, fibrosis, etc. Nonetheless, the currently available pharmacological tools to control innate immune responses are scarce and ineffective. Therefore, in this new patent, we offer new active principles with outstanding activity to control the activation of the innate immune system in various pathological contexts.
New pharmacologically doped bone implants
The treatment of multiple pathological processes that affect the bone and the joints (fractures, joint degeneration, etc.) requires the placement of bone implants. A significant percentage of these implants fail and must be replaced, entailing a human and economic cost. Various factors have been related to implant failure, including poor osteointegration, aseptic loosening, peri-implant inflammation, and local bone deficiencies. In view of this problem, our new patent offers a new generation of pharmacologically treated implants that can prevent implant failure and facilitate personalized medicine with implants adapted to the needs of patients